Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis
详细信息 查看全文
- 作者：Yu Xuan Koo (12) kooyuxuan@hotmail.com <br>Matthew Tay (12) taymat@gmail.com <br>Yii Ean Teh (12) yeanz87@yahoo.com <br>David Teng (12) kpteng@nus.edu.sg <br>Daniel S. W. Tan (1) daniel.tan.s.w@nccs.com.sg <br>Iain B. H. Tan (1) iain.tan.b.h@nccs.com.sg <br>David W. M. Tai (1) davidtai1979@gmail.com <br>Richard Quek (1) dmorqhh@nccs.com.sg <br>Miriam Tao (1) dmomit@nccs.com.sg <br>Soon Thye Lim (1) dmolst@nccs.com.sg
- 关键词：Lymphoma – ; Non ; Hodgkin – ; Hepatitis B virus – ; Hepatitis B surface antigens – ; Lamivudine – ; Rituximab – ; Antibodies – ; Monoclonal
- 刊名：Annals of Hematology
- 出版年：2011
- 出版时间：October 2011
- 年：2011
- 卷：90
- 期：10
- 页码：1219-1223
- 全文大小：91.8 KB
- 参考文献：1. Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST (2010) Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 116(1):115–121. doi: <br>2. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferm茅 C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 23(18):4117–4126. doi: <br>3. Dall’Era M, Wofsy D (2010) Biologic therapy for systemic lupus erythematosus. Discov Med 9(44):20–23 <br>4. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA (2009) Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 18(9):767–776. doi: <br>5. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, Leung N, Luk JM, Lie AK, Kwong YL, Liang R, Lau GK (2006) Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131(1):59–68. doi: <br>6. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, Kuwahara N, Tomimasu R, Tsuneyoshi N, Funai N, Sueoka E (2009) Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 20(12):2013–2017 <br>7. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27(4):605–611. doi: <br>8. Niitsu N, Hagiwara Y, Tanae K, Kohri M, Takahashi N (2010) Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J Clin Oncol. doi: <br>9. Ji D, Cao J, Hong X, Li J, Wang J, Chen F, Wang C, Zou S (2010) Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol 85(3):243–250. doi: <br>10. Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, Takeuchi M (2010) Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. doi: <br>11. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY (2010) Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 89(3):255–262. doi: <br>12. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148(7):519–528 <br>13. Lalazar G, Rund D, Shouval D (2007) Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 136(5):699–712. doi: <br>14. Liang R (2009) How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood 113(14):3147–3153. doi: <br>15. Delaney WE 4th, Borroto-Esoda K (2008) Therapy of chronic hepatitis B: trends and developments. Curr Opin Pharmacol 8(5):532–540 <br>16. Firpi RJ, Nelson DR (2008) Management of viral hepatitis in hematologic malignancies. Blood Rev 22(3):117–126 <br>17. Cheng PN, Chang TT (2008) Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients. Expert Rev Anti Infect Ther 6(5):569–579
- 作者单位：1. Department of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore, 169610 Singapore2. Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- 刊物类别：Medicine
- 刊物主题：Medicine & Public Health<br>Hematology<br>Oncology<br>
- 出版者：Springer Berlin / Heidelberg
- ISSN：1432-0584
文摘
The use of rituximab has been associated with increased risk of hepatitis B virus (HBV) reactivation in patients who are hepatitis B surface antigen (HBsAg) negative and antihepatitis B core antibody (anti-HBc) positive. We aim to determine the rate of HBV reactivation in this group of patients who received rituximab-containing combination chemotherapy without concomitant antiviral prophylaxis and to identify potential risk factors for reactivation. Sixty-two HBsAg negative/anti-HBc positive patients with B-cell lymphoma treated with rituximab-based immunochemotherapy from 2006 to 2009 were included. None of the patients received concomitant antiviral prophylaxis. In this cohort, 48 (77%) patients received rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), eight (13%) received rituximab with cyclophosphamide, vincristine and prednisolone, and six (10%) received other chemotherapy regimens. Two patients suffered HBV reactivation; both were above 70 years of age, received R-CHOP chemotherapy and were negative for antihepatitis B surface antibody (anti-HBs) at baseline. One of the two patients reactivated shortly after completion of R-CHOP chemotherapy while the other reactivated during rituximab maintenance treatment. Thus, the overall reactivation rate in this cohort of patients is 3% (2/62), 4% (2/48), and 25% (1/4) in patients who received R-CHOP chemotherapy and who received rituximab maintenance, respectively. The rate of HBV reactivation is low in patients who are HBsAg negative/anti-HBc positive receiving rituximab-based combination chemotherapy without concomitant antiviral prophylaxis. However, elderly patients, particularly those without anti-HBs, seemed particularly at risk.